40 patents currently held
2 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in Apr 2027. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
4
Ending by 2030
Apr 2027
Next term end
26
Patent families
When these terms end
Held patents by the year their term ends
notable patents
fee due within 90 days
all others
Updated Nov 17, 2026 · includes USPTO assignment data published Nov 16, 2026, status data published Nov 17, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Sep 2029 · High confidence
Also notable
Ends Aug 2038 · High confidence
Also notable
Ends Aug 2038 · High confidence
Exosome transfer of nucleic acids to cells
US 9,085,778
The most cited patent in this portfolio, cited by 50 later US patents, top 10% of utility patents granted in 2015 in our data. Protection runs to 2029.
Preparation of Therapeutic Exosomes Using Membrane Proteins
US 10,195,290
Cited by 17 later US patents, top 25% of utility patents granted in 2019 in our data, and renewed at 2 of 3 maintenance windows. Protection runs to 2038.
Exosomes for Immuno-Oncology and Anti-Inflammatory Therapy
US 10,723,782
Cited by 10 later US patents, top 25% of utility patents granted in 2020 in our data. Protection runs to 2038. A terminal disclaimer caps this term to an earlier patent's.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Dec 20, 2026The maintenance fee for Preparation of Therapeutic Exosomes Using Membrane Proteins (US 11,679,164) comes due Dec 20, 2026. Unpaid by Jun 21, 2027, it lapses early.
- 2 fees due Jan 21 to 25, 2027 · next Jan 21
- 1 fee due Feb 6, 2027The maintenance fee for Delivery of Therapeutic Agent (US 10,370,663) comes due Feb 6, 2027. Unpaid by Aug 6, 2027, it lapses early.
- 1 fee due Aug 18, 2027The maintenance fee for Preparation of Therapeutic Exosomes Using Membrane Proteins (US 10,561,740) comes due Aug 18, 2027. Unpaid by Feb 18, 2028, it lapses early.
- 1 fee due Sep 12, 2027The maintenance fee for Flash Nozzle Assembly (US 11,925,954) comes due Sep 12, 2027. Unpaid by Mar 13, 2028, it lapses early.
Recent changes
- 5 of the patents on this record were granted since Aug 19, 2026
What they patent
The 5 largest of its 26 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
| Preparation of Therapeutic Exosomes Using Membrane Proteins | 4 in force | to Aug 2038 |
| Exosome transfer of nucleic acids to cells | 4 in force | to Sep 2029 |
| Exosomes for Immuno-Oncology and Anti-Inflammatory Therapy | 3 in force | to Aug 2038 |
| Process for Preparing Extracellular Vesicles | 2 in force | to May 2041 |
| Extracellular Vesicles for Vaccine Delivery | 2 in force | to Mar 2040 |
Patents held now
Soonest term end first.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,629,929 | Exosome Transfer of Nucleic Acids to Cells In force · High confidence | In force | High confidence | |
| US 9,889,210 | Exosome Transfer of Nucleic Acids to Cells In force · High confidence | In force | High confidence | |
| US 10,695,443 | Exosome Transfer of Nucleic Acids to Cells In force · High confidence | In force | High confidence | |
| US 9,085,778 | Exosome transfer of nucleic acids to cells In force (reinstated) · High confidence | In force (reinstated) | High confidence | |
| US 9,856,477 | Delivery of Therapeutic Agent In force · High confidence | In force | High confidence | |
| US 10,370,663 | Delivery of Therapeutic Agent In force (reinstated) · High confidence | In force (reinstated) | High confidence | |
| US 11,324,699 | Lipid Multiparticulate Formulations In force · Medium confidence | In force | Medium confidence | |
| US 12,133,911 | Formulations to Achieve Rapid Dissolution of Drug from Spray-Dried Dispersions in Capsules In force · High confidence | In force | High confidence | |
| US 12,158,424 | Methods of Measuring Exosomes Using Intrinsic Fluorescence In force · High confidence | In force | High confidence | |
| US 10,195,290 | Preparation of Therapeutic Exosomes Using Membrane Proteins In force · High confidence | In force | High confidence |
Also on record, not counted in the 40: 2 patents in force now held by others · 1 patent ended · 51 applications pending · 13 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.